Aeolus Pharmaceuticals Receives $690,050 New Funding Round
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=32cf15df-6d7a-4d91-aecd-14de2b4546e4&Preview=1 - Date
4/19/2012 - Company Name
Aeolus Pharmaceuticals - Mailing Address
26361 Crown Valley Parkway Mission Viejo, CA 92691 - Company Description
Aeolous Pharmaceuticals (BB: AOLS) is a biopharmaceutical company that is developing a new class of catalytic antioxidant compunds, referred to as manganoporphyrins, for diseases and disorders of the central nervous system, respiratory system, autoimmune system, and oncology. Over the past decade, Aeolus has synthesizec, developed, and analyzed approximately 200 proprietary catalytic antioxidant compounds, all of which have the same core chemical structure. - Website
http://www.AeolousPharma.com - Transaction Type
Venture Equity - Transaction Amount
$690,050 - Transaction Round
Undisclosed - Proceeds Purposes
Proceeds purposes were not disclosed. SEC regulatory filing. - M&A Terms
- Venture Investor
Undisclosed
